[go: up one dir, main page]

BRPI0508254A - methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents - Google Patents

methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents

Info

Publication number
BRPI0508254A
BRPI0508254A BRPI0508254-4A BRPI0508254A BRPI0508254A BR PI0508254 A BRPI0508254 A BR PI0508254A BR PI0508254 A BRPI0508254 A BR PI0508254A BR PI0508254 A BRPI0508254 A BR PI0508254A
Authority
BR
Brazil
Prior art keywords
compositions
cox
combination
psychiatric disorders
treating
Prior art date
Application number
BRPI0508254-4A
Other languages
Portuguese (pt)
Inventor
Diane Stephenson
Duncan P Taylor
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of BRPI0508254A publication Critical patent/BRPI0508254A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

MéTODOS E COMPOSIçõES PARA O TRATAMENTO OU PREVENçãO DE DISTúRBIOS PSIQUIáTRICOS COM INIBIDORES DE COX-2 SOZINHOS E EM COMBINAçãO COM AGENTES ANTIDEPRESSIVOS A presente invenção se refere a um método inédito de tratamento e/ou prevenção de distúrbios psiquiátricos em um paciente pela administração ao paciente de pelo menos um inibidor de Cox-2, sozinho ou em combinação com um ou mais agentes antidepressivos. São também descritas composições, composições farmacêuticas e kits.METHODS AND COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF PSYCHIATRIC DISORDERS WITH ALONE COX-2 INHIBITORS AND IN COMBINATION WITH ANTIDEPRESSIVE AGENTS The present invention relates to a novel method of treating and / or preventing psychiatric disorders in a patient by administering a patient to a patient. at least one Cox-2 inhibitor, alone or in combination with one or more antidepressant agents. Compositions, pharmaceutical compositions and kits are also described.

BRPI0508254-4A 2004-03-02 2005-03-02 methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents BRPI0508254A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54928104P 2004-03-02 2004-03-02
PCT/US2005/006818 WO2005084654A2 (en) 2004-03-02 2005-03-02 Methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents

Publications (1)

Publication Number Publication Date
BRPI0508254A true BRPI0508254A (en) 2007-07-24

Family

ID=34919463

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0508254-4A BRPI0508254A (en) 2004-03-02 2005-03-02 methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents

Country Status (5)

Country Link
EP (1) EP1725222A2 (en)
JP (1) JP2007526328A (en)
BR (1) BRPI0508254A (en)
CA (1) CA2556380A1 (en)
WO (1) WO2005084654A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0516000A (en) * 2004-10-15 2008-05-06 Pfizer use of a compound or a pharmaceutically acceptable salt, solvate, hydrate or optical isomer thereof, method for treating bipolar disorder in a mammal in need thereof, and kit for use in treating bipolar disorder
EP1976495A2 (en) * 2006-01-06 2008-10-08 Aarhus Universitet Compounds acting on the serotonin transporter
EA014820B1 (en) * 2006-04-04 2011-02-28 Эмодис Гмбх Use of compositions containing buprenorphine kappa opioid receptor antagonist-for the treatment of dissociative disorders
CN101878042B (en) 2007-11-28 2013-06-19 尼克塔治疗公司 Oligomer-tricyclic conjugates
FR2935611B1 (en) * 2008-09-10 2010-10-15 Commissariat Energie Atomique USE OF ANTI-CONNEXINE AGENTS FOR MODULATING THE THERAPEUTIC EFFECT OF PSYCHOTROPIC MOLECULES
US8198268B2 (en) 2008-10-31 2012-06-12 Janssen Biotech, Inc. Tianeptine sulfate salt forms and methods of making and using the same
GB0822077D0 (en) * 2008-12-03 2009-01-07 Minster Res Ltd Novel treatments
JP6051466B2 (en) * 2011-10-18 2016-12-27 ラクオリア創薬株式会社 Pharmaceutical composition
WO2013179153A1 (en) * 2012-05-10 2013-12-05 Mahesh Kandula Compositions and methods for treatment of neurological degenerative disorders and neurological diseases
GB201416017D0 (en) * 2014-09-10 2014-10-22 New Royal Holloway & Bedford An Anticonvulsant Compound
WO2017213977A1 (en) * 2016-06-07 2017-12-14 Mehra Akhil Methods and compositions for the treatment of trauma and stressor-related disorders
RU2762896C2 (en) 2016-12-20 2021-12-23 Лтс Ломанн Терапи-Систем Аг Transdermal therapeutic system containing asenapine
RU2764443C2 (en) 2016-12-20 2022-01-17 Лтс Ломанн Терапи-Систем Аг Transdermal therapeutic system containing azenapine and polysiloxane or polyisobutylene
BR112019027037B1 (en) 2017-06-26 2022-04-05 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer, and process for making an asenapine-containing layer for use in said system
KR20200026920A (en) 2017-06-30 2020-03-11 체이스 테라퓨틱스 코포레이션 NK-1 antagonist compositions for treating depression and methods for use in treating depression
WO2019060729A1 (en) * 2017-09-21 2019-03-28 Tremeau Pharmaceutials, Inc. An ingestible product and a method of using the same
CN112118838A (en) 2017-12-05 2020-12-22 赛诺维信制药公司 Non-racemic mixtures and their uses
CN118955352A (en) 2017-12-05 2024-11-15 赛诺维信制药公司 Crystalline forms and methods of preparing the same
CN112533593A (en) 2018-06-20 2021-03-19 罗曼治疗系统股份公司 Transdermal therapeutic system comprising asenapine
US11648213B2 (en) 2018-06-20 2023-05-16 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
WO2020247627A1 (en) 2019-06-04 2020-12-10 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4205577B2 (en) * 2001-06-19 2009-01-07 ミュラー，ノルベルト Use of COX-2 inhibitors for the treatment of schizophrenia, delusional disorder, affective disorder, autism or tic disorder

Also Published As

Publication number Publication date
JP2007526328A (en) 2007-09-13
WO2005084654A3 (en) 2005-11-17
CA2556380A1 (en) 2005-09-15
WO2005084654A2 (en) 2005-09-15
EP1725222A2 (en) 2006-11-29

Similar Documents

Publication Publication Date Title
BRPI0508254A (en) methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents
BR112021017350A2 (en) Combination of antibody-pyrrolobenzodiazepine derivative conjugate and parp inhibitor
CY1120961T1 (en) ORAL DOSAGE CONTAINERS INCLUDING ANTI-PETROLEUM PATENT AND ACID INHIBITOR
BRPI0408902A (en) selective cyclooxygenase-2 inhibitor compositions and 5-ht 1b / 1d agonists for the treatment and prevention of migraine
BR0304648A (en) Combination of cyclooxygenase-2 inhibitors and thalidomide for the treatment of neoplasia
NI200900106A (en) INHIBITORS OF THE ACTIVITY OF THE AKT.
EA200800006A1 (en) TRIAZOLOPIRIDIN AS AN INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE I
IL195030A (en) IV dpp inhibitor assemblies
CL2008001782A1 (en) Use of a composition comprising a compound derived from heterocycle to treat or prevent the loss of intestinal flow; composition comprising said compound; and kit that includes the composition.
EA201270184A1 (en) TREATMENT OF LIVER DISORDERS PI3K INHIBITORS
EA200900828A1 (en) COMPOUNDS AND COMPOSITIONS AS AN INHIBITOR ACTIVITY OF THE CANANABINOID RECEPTOR 1
ECSP077980A (en) AKT ACTIVITY INHIBITORS
BRPI0716069A2 (en) compound, pharmaceutical composition, and method for treating a disorder
NO20083836L (en) N hydroksyakrylamidforbindelser
ATE548034T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING DROXIDOPA
DE602006013191D1 (en) SUBSTITUTED 1H-BENZIMIDAZOLE-4-CARBOXYLIC ACIDS ARE EFFECTIVE PARP INHIBITORS
CL2009000803A1 (en) Use of a pegylated variant of igf-1 to treat, prevent a neuromuscular disorder; method for the treatment, prevention and / or delay of a neuromuscular disorder; composition comprising the modified igf-1 variant
WO2008042480A3 (en) Epoxide inhibitors of cysteine proteases
EA200800755A1 (en) IKK INHIBITORS INTRODUCED FOR THE TREATMENT OF ENDOMETRIOSIS
BRPI0508051A (en) heteroarylaminopyrazole derivatives usable for the treatment of diabetes
BR0316723A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
TW200507840A (en) Method of treating multiple myeloma
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
NO20091495L (en) Pyrazolopyrimidinderivat
DOP2007000073A (en) COMPOUNDS TO TREAT PULMONARY HYPERTENSION

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 5A E 6A ANUIDADE(S).

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE A 8.6 NA RPI 2099 DE 29/03/2011.